Home New Customer? Create Account
Member Login:

Phage

OG65 - pSF-CMV-COOH-P2A-3

PRICE

Starting at: $288.00

Please Choose:

Shipping Option



Enter Quantity:


This plasmid is compatible with all of the other DNA sequences available on this site, which are all sold in the same backbone. This flexibility allows you to create any vector you require, with a variety of functions, simply by compiling the relevant sections from our product range.

Product Code: OG65

Size (bp): 4280

Bacterial Antibiotic Selection: Kanamycin

Origin and Compatibility: pUC high copy, derived from pBR322   

Copy Number: 500-700 copies per cell

Promoter: Cytomegalovirus (CMV) immediate early promoter

Purpose: This vector adds a Foot and Mouth Disease P2A peptide between the primary MCS (NotI-XbaI, but XbaI is ablated in this vector) and the fusion MCS (ClaI-NheI). The P2A peptide coding sequence is GSGATNFSLLKQAGDVEENPGP. The peptide self-cleaves between the penultimate glycine residue and the final proline residue. This leaves the first (upstream) protein in the polypeptide with the majority of the amino acids of the P2A peptide on the C-terminus, whilst the last (downstream) protein has a proline remaining on the N-terminus. We have not confirmed if secretory proteins are able to detach from cytosolic proteins when fused using this method. The intracellular trafficking of your proteins should therefore be considered.

Frame: For reference, the coding sequence of the P2A peptide is two base pairs out of frame with the TAG stop codon that is found within the upstream XbaI site.

Inserting a Gene: Each restriction site in this vector has a purpose and allows the insertion of specific pre-designed DNA sequences. To insert a gene, we recommend using any sites between (and including) the HindIII and XbaI sites. By doing this you will be able to insert most of our other products upstream, or downstream, of your gene. Click here to read more about the purpose of each restriction site.

Intellectual Property Status: According to our IP-friendly policy, this plasmid is sold free of reach-through rights on any derivatives you may create.

Quality Sequencing Analysis: This vector has been fully sequenced using primers F1-F10. The sequences and details of these primers are available through our website.

Genetic Modifications to standard parts:

  • CMV promoter – an NcoI site has been ablated in the CMV promoter. This change does not reduce expression.
  • KanR cassette – This KanR resistance region is not a wild type sequence, it has been modified to remove all restriction sites that conflict with the SnapFast system and to retain a high level of antibiotic resistance. It has been validated in E.coli.